Phase Three - managing the risk of CVD in patients with Type 2 Diabetes
Phase Three of the West Yorkshire Healthy Hearts project focuses on reducing the risk of cardiovascular disease (CVD) in patients with Type 2 Diabetes by introducing the addition of Sodium-glucose co-transporter-2 inhibitor (SGLT2i) medication if their current treatment is not adequately controlling their HBA1c levels.
Sodium-glucose co-transporter-2 inhibitor (SGLT2i) therapies have robust evidence for significantly reducing CVD outcomes in people with Type 2 Diabetes who have either established CVD or are at risk of developing CVD.
The proposed diabetes treatment guidance has been developed for use in primary care and has been created following extensive stakeholder engagement across West Yorkshire with the approval of the West Yorkshire Area Prescribing Committee.
The simplified treatment guidance, adapted from the work that has started to be developed in Leeds and other regions across the country, aims to facilitate the work of primary care in managing the CVD risk in patients with Type 2 Diabetes. Evidence shows that SGLT2i can lower HBA1c levels significantly, reduce weight and lower blood pressure.
Clinical resources for primary care
Treatment guidance - coming soon
- UCLPartners searches developed by UCLPartners clinical team working with the Clinical Effectiveness Group based at Queen Mary University of London